ArticleAnnals of medicine and surgery (2012)2025
AI in drug repurposing for cancer therapies.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) is transforming drug discovery by enabling the rapid identification of existing drugs with potential anti-cancer properties, a process known as drug repurposing. This approach offers a cost-effective and time-efficient alternative to traditional drug development, particularly in oncology, where the need for novel therapies is urgent. AI-driven methods, including machine learning (ML) and deep learning (DL), analyze vast datasets to uncover hidden drug-disease relationships, predict drug efficacy, and optimize therapeutic combinations. This letter highlights the transformative potential of AI in drug repurposing for cancer therapies, supported by successful examples from recent research. We also discuss the challenges and ethical considerations of integrating AI into drug repurposing efforts, emphasizing the need for robust validation and regulatory oversight to ensure patient safety and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.